Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins
about
Developing irreversible inhibitors of the protein kinase cysteinomeStructural Framework for Covalent Inhibition of Clostridium botulinum Neurotoxin A by Targeting Cys165Reversible targeting of noncatalytic cysteines with chemically tuned electrophilesCovalent docking of large libraries for the discovery of chemical probesMining a cathepsin inhibitor library for new antiparasitic drug leadsThe Die Is Cast: Precision Electrophilic Modifications Contribute to Cellular Decision MakingPrediction of ligand-binding sites of proteins by molecular docking calculation for a random ligand libraryStrategies for discovering and derisking covalent, irreversible enzyme inhibitors.Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay.Protocol for rational design of covalently interacting inhibitors.Biophysical limits of protein-ligand binding.Mapping a protein recognition centre with chiral photoactive ligands. An integrated approach combining photophysics, reactivity, proteomics and molecular dynamics simulation studiesFragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.Additivity-based design of the strongest possible turkey ovomucoid third domain inhibitors for porcine pancreatic elastase (PPE) and Streptomyces griseus protease B (SGPB).Inhibitors of cathepsin K: a patent review (2004 - 2010).Discovery of small molecule cancer drugs: successes, challenges and opportunities.Dissection of H-bonding interactions in a glycolic acid-water dimer.Targeted Covalent Inhibitors for Drug Design.Association models for binding of molecules to nanostructures.Covalent inhibition of protein tyrosine phosphatases.Observations on screening-based research and some concerning trends in the literature.Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG Iα (Protein Kinase G Iα).Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.Two-component covalent inhibitor.A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints.Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition.Synthesis and Deployment of an Elusive Fluorovinyl Cation Equivalent: Access to Quaternary α-(1'-Fluoro)vinyl Amino Acids as Potential PLP Enzyme Inactivators.Quantitative probing of subtle interactions among H-bonds in alpha hydroxy carboxylic acid complexes.Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations.Focusing on probe-modified peptides: a quick and effective method for target identification.Reversible covalent inhibition of a protein target.The Taxonomy of Covalent InhibitorsThe Effect of CYP2B6, CYP2D6, and CYP3A4 Alleles on Methadone Binding: A Molecular Docking Study
P2860
Q27027983-B3ED084B-D385-4F02-B81B-9FF1AC75C94CQ27671266-A22A738D-2315-4385-A729-D078781F98BBQ27678280-F50D1AEF-D196-4BFE-B5D6-469A95BCB55FQ28250319-B972D75A-C87F-4A9E-9BC8-B02484A98CA3Q28478016-22DC8B5B-F1F0-4289-B5BC-DFED7C331847Q28821689-FC9816F6-5472-4DB8-BC75-7C70189BFE7FQ33743244-DD464B0A-75EE-41D0-AE25-15B6B4756F16Q34023143-37EDB8E6-5866-42CB-951B-B9E1F29D2695Q34160457-CDC11B99-0B28-4F4D-B395-16BDF20CAB1CQ34991036-5A75C003-3F73-445F-8AA6-0F2210705D42Q35273893-49E5678B-82E9-4C1B-9528-D4F3A6F71B4AQ36191972-ACA0EFC2-5DAC-49BC-9614-E388BC2B7715Q36383970-D95D425B-5D80-4346-B2DB-BCC6BF79CB4CQ36808252-015316BD-E086-4359-AAAE-D56F9B80C6ABQ37199690-63675D7F-79E1-446C-A511-46326F15892AQ37933395-56BE95B2-2459-4292-9856-D5BFD4C09EB9Q37996113-67CE4CB4-9092-4254-9C43-DA8A7B0FD3C0Q38682485-B95F427F-758B-4CD1-804F-F79A4D5675A5Q38931379-8FD33639-8EE4-482F-8B7F-C4C12F3CF291Q39317723-7278F844-5821-40D5-942D-08B44D0CD8CDQ39324501-550FC97E-9515-4448-BA72-9EB8EEA65509Q39769260-0BB6B79E-F36A-4B58-83FD-E8E624DC6EDCQ41305323-5345EB69-FD68-40BE-980D-812CE2C4DF1FQ42017198-440A157E-8306-4637-A424-051AA17ADC74Q42086341-88090302-8C48-4F52-AE87-24EFFE8EEF6DQ42148589-A4BC1E14-5876-43B7-BF3E-DAD998EC7DF3Q42960886-4EF7966F-4AD9-4AB5-A5D2-266650C4606AQ43816076-647BE8F5-28D1-4A47-9F5A-6878D55F1D82Q46648296-CF05FFE8-4A18-4ED0-A8A1-7A3001977C0AQ47804072-8A7B6ABB-2B74-451C-A641-992E825EFC7DQ47966596-2F0211B5-8F5F-440B-84DB-56CADC479003Q51533605-1C672002-11E8-420F-81D1-8421EA231093Q51604061-A2FE1ADD-1EB0-46E1-9465-9882677D88E9Q51626316-B9597BA3-413B-40BF-8C16-63050AA0F003Q54496610-69AB5C9A-B6B7-4503-AD90-F78E3FD8BB1FQ56675654-32F0FDDD-A0C4-4F76-B28A-3855A175AD7EQ59009311-16B634B9-0634-4C7C-85F1-A76A267E1BFC
P2860
Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@ast
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@en
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@nl
type
label
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@ast
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@en
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@nl
prefLabel
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@ast
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@en
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@nl
P2093
P2860
P3181
P356
P1476
Beyond picomolar affinities: q ...... t binding of drugs to proteins
@en
P2093
Adam J T Smith
Andrew G Leach
Xiyun Zhang
P2860
P304
P3181
P356
10.1021/JM800498E
P407
P50
P577
2009-01-22T00:00:00Z